SEC Tracker
Get the app
PASG · XBRL financial data

Passage BIO financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (PASG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Research and development———61,41940,17923,276
General and administrative30,11460,05649,34141,58024,98819,875
Operating income (loss)(112,902)(185,729)(138,394)(108,389)(70,400)(49,296)
Interest income670343————
Other income (expense)——2,2696,3275,6333,774
Income tax expense (benefit)————00
Net income (loss)(112,232)(185,386)(136,125)(102,062)(64,767)(45,522)
Earnings per share, basic‡ USD per share(58.20)(69.60)(50.00)(37.20)(21.40)(14.35)
Earnings per share, diluted‡ USD per share(58.20)(69.60)(50.00)(37.20)(21.40)(14.35)
Weighted average shares, basic‡ thousands of shares1,9312,6672,7212,7373,0203,173
Weighted average shares, diluted‡ thousands of shares1,9312,6672,7212,7373,0203,173
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal years (PASG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents135,002128,96534,60121,70937,57346,303
Marketable securities169,815186,808155,00992,58539,1830
Prepaid and other current assets1,4051,726926923838629
Total current assets317,183325,066197,044117,95978,81547,762
Property and equipment, net2,79523,80622,51515,2959,3314,107
Right-of-use asset——19,72316,85813,80310,168
Total assets328,007355,076243,549150,545102,41262,281
Accounts payable5,2659,4484,0651,2987421,113
Total current liabilities21,17529,49818,35116,34119,36323,083
Lease liability, non-current——23,83222,92121,78820,443
Total liabilities23,29336,41942,18339,26241,15143,526
Accumulated deficit(170,895)(356,281)(492,406)(594,468)(659,235)(704,757)
Total stockholders' equity304,714318,657201,366111,28361,26118,755
Total liabilities and equity328,007355,076243,549150,545102,41262,281
Common shares outstanding (cover page)‡ thousands of shares2,6922,7152,7312,7803,1073,208
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal years (PASG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(112,232)(185,386)(136,125)(102,062)(64,767)(45,522)
Stock-based compensation14,58032,69118,95410,9215,8203,001
Depreciation and amortization8001,5433,6793,7213,081728
Net cash from operating activities(80,520)(126,879)(118,210)(78,264)(47,956)(31,509)
Net cash from investing activities(172,106)(45,814)25,19965,23754,94640,216
Proceeds from issuing common stock228,262165,806————
Net cash from financing activities228,754166,656(1,353)1358,87423
Net change in cash(23,872)(6,037)(94,364)(12,892)15,8648,730

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Passage BIO24,155not reported(9,181)*3.2M2.6 quarters 10-QJun 30, 2026
Pulmatrix2,168not reported(1,106)*3.7M2.0 quarters 10-QJun 30, 2026
Scynexis10,487235(14,885)*9.9M3.6 quarters 10-QJun 30, 2026
Palatin Technologies7,492301*(2,690)*1.8M2.8 quarters 10-KJun 30, 2026
Curis5,0730(9,646)*2.1M0.5 quarters 10-QJun 30, 2026
Kala Bio229not reported(1,535)*19.3M4.7 quarters 10-QJun 30, 2026
Lexaria Bioscience3,5000(1,635)*24.8M2.2 quarters 10-QMay 31, 2026
Dyadic International1,425961(1,818)*36.4M1.7 quarters 10-QJun 30, 2026
Outlook Therapeutics11,242not reported(21,011)*243.4M0.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.